Actively Recruiting
Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2024-08-20
364
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
W
Women's Hospital School Of Medicine Zhejiang University
Lead Sponsor
P
Peking University First Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Postpartum depression is a common psychological abnormality during the puerperium, which seriously affects maternal and neonatal health. Esketamine, the S-enantiomer of ketamine, is twice as potent as ketamine and can be safely used for cesarean section and labor analgesia. However, it is not clear whether esketamine used for epidural labor analgesia can significantly reduce the incidence of postpartum depression. This study intends to explore the incidence of maternal prenatal depression and to investigate the effect of esketamine for epidural labor analgesia on postpartum depression and maternal and neonatal outcomes in parturients with prenatal depression through a multi-center, large-scale and high-quality clinical trail, in order to provide a clinical basis and theoretical basis for the application of esketamine used for epidural labor analgesia in postpartum depression and further reduce the incidence of postpartum depression, promote maternal and infant health, and ensure maternal and infant safety .
CONDITIONS
Official Title
Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Full-term pregnancy
- Antenatal depressive state with EPDS score of 10 or higher and no depressive diagnosis by a psychiatrist
- Planned epidural labor analgesia
- Signed informed consent
You will not qualify if you...
- History of definite psychiatric disorders such as depression or schizophrenia
- Presence of severe pregnancy complications including severe preeclampsia, placental implantation, HELLP syndrome, placenta praevia, or placenta abruptio
- ASA classification of grade III or higher
- Contraindications to ketamine or S-ketamine such as refractory hypertension, severe cardiovascular disease (cardiac function class III or higher), or hyperthyroidism
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Women's hospital, school of medicine, Zhejiang university
Hangzhou, Zhejiang, China, 331000
Actively Recruiting
Research Team
X
Xinzhong Chen, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here